KTTA Key Statistics, Chart & Performance
The current stock price of KTTA is 1.17 USD. In the past month the price increased by 139.95%. In the past year, price decreased by -57.14%.
KTTA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.33 | 406.30B | ||
| AMGN | AMGEN INC | 15.27 | 179.83B | ||
| GILD | GILEAD SCIENCES INC | 15.34 | 155.92B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.67 | 117.47B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.41 | 82.37B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 785.67 | 52.94B | ||
| INSM | INSMED INC | N/A | 37.84B | ||
| NTRA | NATERA INC | N/A | 32.51B | ||
| BIIB | BIOGEN INC | 10.53 | 25.87B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.5 | 22.16B | ||
| INCY | INCYTE CORP | 15.64 | 19.72B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About KTTA
Company Profile
Pasithea Therapeutics Corp. is a biotechnology company focused on the research and discovery of new and treatments for psychiatric and neurological disorders. The company is headquartered in Miami Beach, Florida and currently employs 4 full-time employees. The company went IPO on 2021-08-13. The firm is advancing a pipeline of three therapeutic product candidates, with a focus on its lead product candidate, PAS-004, a macrocyclic mitogen-activated protein kinase, or MEK inhibitor. PAS-004 is a small molecule allosteric inhibitor of MEK 1 and 2 (MEK 1/2) for potential use in the treatment of a range of RASopathies, including neurofibromatosis type 1 (NF1) and a number of oncology indications, among others. Its remaining two programs, PAS-001 and PAS-003, are in the earlier stages of development and are based on novel targets for the treatment of CNS disorders that it believes address limitations in the treatment paradigm of the indications it plans to address, which are amyotrophic lateral sclerosis (ALS) for its PAS-003 program, and schizophrenia for its PAS-001 program.
Company Info
PASITHEA THERAPEUTICS CORP
1111 Lincoln Road, Suite 500
Miami Beach FLORIDA US
CEO: Tiago Reis Marques
Employees: 4
Phone: 17025144174
PASITHEA THERAPEUTICS CORP / KTTA FAQ
What does KTTA do?
Pasithea Therapeutics Corp. is a biotechnology company focused on the research and discovery of new and treatments for psychiatric and neurological disorders. The company is headquartered in Miami Beach, Florida and currently employs 4 full-time employees. The company went IPO on 2021-08-13. The firm is advancing a pipeline of three therapeutic product candidates, with a focus on its lead product candidate, PAS-004, a macrocyclic mitogen-activated protein kinase, or MEK inhibitor. PAS-004 is a small molecule allosteric inhibitor of MEK 1 and 2 (MEK 1/2) for potential use in the treatment of a range of RASopathies, including neurofibromatosis type 1 (NF1) and a number of oncology indications, among others. Its remaining two programs, PAS-001 and PAS-003, are in the earlier stages of development and are based on novel targets for the treatment of CNS disorders that it believes address limitations in the treatment paradigm of the indications it plans to address, which are amyotrophic lateral sclerosis (ALS) for its PAS-003 program, and schizophrenia for its PAS-001 program.
What is the current price of KTTA stock?
The current stock price of KTTA is 1.17 USD. The price increased by 0.86% in the last trading session.
Does KTTA stock pay dividends?
KTTA does not pay a dividend.
What is the ChartMill technical and fundamental rating of KTTA stock?
KTTA has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
On which exchange is KTTA stock listed?
KTTA stock is listed on the Nasdaq exchange.
What is the employee count for KTTA stock?
PASITHEA THERAPEUTICS CORP (KTTA) currently has 4 employees.
What is the next earnings date for KTTA stock?
PASITHEA THERAPEUTICS CORP (KTTA) will report earnings on 2026-03-23.
KTTA Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to KTTA. When comparing the yearly performance of all stocks, KTTA turns out to be only a medium performer in the overall market: it outperformed 48.66% of all stocks.
KTTA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to KTTA. The financial health of KTTA is average, but there are quite some concerns on its profitability.
KTTA Financial Highlights
Over the last trailing twelve months KTTA reported a non-GAAP Earnings per Share(EPS) of -5.21. The EPS increased by 63.76% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -99% | ||
| ROE | -110.55% | ||
| Debt/Equity | 0 |